niacin has been researched along with Brain Ischemia in 15 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
Excerpt | Relevance | Reference |
---|---|---|
"In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol." | 9.17 | Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. ( Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS, 2013) |
"In this study we examined the effect of combination treatment of experimental stroke with Niaspan, a prolonged-release formulation of Niacin (vitamin B3), and Simvastatin, a cholesterol-lowering drug, on functional outcome, axonal damage, axonal density and the of Iba-1 immunoreactive microglia expression in the ischemic brain of rats." | 7.76 | Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. ( Chen, J; Chopp, M; Cui, X; Lu, M; Roberts, C; Shehadah, A, 2010) |
"In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol." | 5.17 | Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. ( Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS, 2013) |
"In this study we examined the effect of combination treatment of experimental stroke with Niaspan, a prolonged-release formulation of Niacin (vitamin B3), and Simvastatin, a cholesterol-lowering drug, on functional outcome, axonal damage, axonal density and the of Iba-1 immunoreactive microglia expression in the ischemic brain of rats." | 3.76 | Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. ( Chen, J; Chopp, M; Cui, X; Lu, M; Roberts, C; Shehadah, A, 2010) |
"It is shown that, in rats with global cerebral ischemia modeled by a complete irreversible occlusion of the common carotid artery and forced hypotension, the hemostasis is characterized by a shift toward hypercoagulation." | 1.38 | [Effect of phenibut and its composition with nicotinic acid on hemostasis in rats with brain ischemia]. ( Kurkin, DV; Litvinov, AA; Tarasov, AS; Tiurenkov, IN; Volotova, EV, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (20.00) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 11 (73.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sun, Y | 1 |
Zhang, Y | 1 |
Li, Y | 1 |
Cheng, J | 1 |
Chen, S | 1 |
Xiao, Y | 1 |
Ao, G | 1 |
Nuñez-Figueredo, Y | 3 |
Ramírez-Sánchez, J | 3 |
Pardo Andreu, GL | 1 |
Ochoa-Rodríguez, E | 3 |
Verdecia-Reyes, Y | 3 |
Souza, DO | 3 |
Teo, KK | 1 |
Goldstein, LB | 1 |
Chaitman, BR | 2 |
Grant, S | 1 |
Weintraub, WS | 1 |
Anderson, DC | 1 |
Sila, CA | 1 |
Cruz-Flores, S | 1 |
Padley, RJ | 1 |
Kostuk, WJ | 1 |
Boden, WE | 2 |
Delgado-Hernández, R | 2 |
Porto-Verdecia, M | 1 |
Marin-Prida, J | 1 |
González-Durruthy, M | 1 |
Uyemura, SA | 1 |
Rodrigues, FP | 1 |
Curti, C | 1 |
Pardo-Andreu, GL | 2 |
Hansel, G | 1 |
Simões Pires, EN | 1 |
Merino, N | 1 |
Valdes, O | 1 |
Parra, AL | 1 |
Salbego, C | 1 |
Costa, SL | 1 |
Gan'shina, TS | 1 |
Kim, GA | 1 |
Gnezdilova, AV | 1 |
Kurdiumov, IN | 1 |
Mirzoian, RS | 1 |
Offermanns, S | 1 |
Schwaninger, M | 1 |
Shehadah, A | 1 |
Chen, J | 1 |
Cui, X | 1 |
Roberts, C | 1 |
Lu, M | 1 |
Chopp, M | 1 |
Probstfield, JL | 1 |
Anderson, T | 1 |
Desvignes-Nickens, P | 1 |
Koprowicz, K | 1 |
McBride, R | 1 |
Teo, K | 1 |
Weintraub, W | 1 |
Nicholls, SJ | 1 |
Tiurenkov, IN | 1 |
Volotova, EV | 1 |
Kurkin, DV | 1 |
Litvinov, AA | 1 |
Tarasov, AS | 1 |
FAZEKAS, JF | 2 |
ALMAN, RW | 2 |
WAHAL, PK | 1 |
MATHUR, KS | 1 |
TICKTIN, HE | 1 |
EHRMANTRAUT, WR | 1 |
SAVARESE, CJ | 1 |
Riasina, TV | 1 |
Korshunova, TS | 1 |
Polianskiĭ, NB | 1 |
Muranov, KO | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289] | Phase 3 | 3,414 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.) | ||
Relationships Between Lipoprotein(a) Levels and Aortic Valve Calcification in Patients With Heterozygous Familial Hypercholesterolemia[NCT02976818] | 173 participants (Actual) | Observational | 2017-04-30 | Completed | |||
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease[NCT02992548] | Phase 4 | 62 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.
Intervention | participants (Number) |
---|---|
ERN + Simvastatin | 45 |
Placebo + Simvastatin | 38 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.
Intervention | participants (Number) |
---|---|
ERN + Simvastatin | 282 |
Placebo + Simvastatin | 274 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months
Intervention | participants (Number) |
---|---|
ERN + Simvastatin | 171 |
Placebo + Simvastatin | 158 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months
Intervention | participants (Number) |
---|---|
ERN + Simvastatin | 156 |
Placebo + Simvastatin | 138 |
3 reviews available for niacin and Brain Ischemia
Article | Year |
---|---|
Multi-targeting effects of a new synthetic molecule (JM-20) in experimental models of cerebral ischemia.
Topics: Animals; Benzodiazepines; Brain Ischemia; Drug Evaluation, Preclinical; Neuroprotective Agents; Niac | 2018 |
Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation.
Topics: 3-Hydroxybutyric Acid; Adenylyl Cyclases; Animals; Brain; Brain Ischemia; Diet, Ketogenic; Dimethyl | 2015 |
CURRENT THERAPEUTIC CONCEPTS OF CEREBRAL AND MYOCARDIAL VASCULAR DISEASE.
Topics: Acetazolamide; Anticoagulants; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Histamin | 1964 |
2 trials available for niacin and Brain Ischemia
Article | Year |
---|---|
Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
Topics: Aged; Atherosclerosis; Brain Ischemia; Delayed-Action Preparations; Female; Follow-Up Studies; Human | 2013 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
10 other studies available for niacin and Brain Ischemia
Article | Year |
---|---|
Synthesis and biological evaluation of novel hydrogen sulfide releasing nicotinic acid derivatives.
Topics: Animals; Brain Ischemia; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationshi | 2016 |
JM-20, a novel benzodiazepine–dihydropyridine hybrid molecule, protects mitochondria and prevents ischemic insult-mediated neural cell death in vitro.
Topics: Animals; Benzodiazepines; Brain Ischemia; Calcium; Cell Death; Cerebellum; Cytochromes c; Dihydropyr | 2014 |
A novel multi-target ligand (JM-20) protects mitochondrial integrity, inhibits brain excitatory amino acid release and reduces cerebral ischemia injury in vitro and in vivo.
Topics: Animals; Benzodiazepines; Brain; Brain Ischemia; Cell Death; Disease Models, Animal; Excitatory Amin | 2014 |
[Effect of S-amlodipine nicotinate on the cerebral circulation in rats under conditions of ischemic and hemorrhagic brain injury].
Topics: Amlodipine; Animals; Animals, Outbred Strains; Brain; Brain Edema; Brain Injuries; Brain Ischemia; L | 2014 |
Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome.
Topics: Amyloid beta-Protein Precursor; Animals; Axons; Brain; Brain Ischemia; Calcium-Binding Proteins; Del | 2010 |
Is niacin ineffective? Or did AIM-HIGH miss its target?
Topics: Brain Ischemia; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; | 2012 |
[Effect of phenibut and its composition with nicotinic acid on hemostasis in rats with brain ischemia].
Topics: Animals; Anticonvulsants; Brain Ischemia; gamma-Aminobutyric Acid; Hemostasis; Male; Niacin; Rats; R | 2012 |
THERAPEUTIC MODALITIES IN THE MANAGEMENT OF CEREBRAL VASCULAR INSUFFICIENCY.
Topics: Anticoagulants; Brain Ischemia; Cerebral Infarction; Cerebrovascular Disorders; Classification; Hist | 1963 |
IMMEDIATE TREATMENT OF OCCLUSIVE CEREBROVASCULAR DISEASE--A COMPARATIVE EVALUATION OF DIFFERENT REGIMES OF TREATMENT.
Topics: Adrenocorticotropic Hormone; Anesthesia; Anesthesia, Conduction; Anesthesia, Spinal; Anticoagulants; | 1963 |
[Anti-ischemic effect of a new derivative of oxynicotinic acid].
Topics: Animals; Arterial Occlusive Diseases; Brain Ischemia; Carotid Artery Diseases; Free Radicals; Lipid | 1994 |